Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Inclusion Criteria:

• HIV-1 positive

• Naïve to antiretroviral therapy including investigational antiretroviral agents

• Not of reproductive potential or, if of reproductive potential agrees to 1) trueabstinence, or 2) use of an acceptable method of birth control during the study

Exclusion Criteria:

• Use of recreational or illicit drugs or has recent history of drug or alcohol abuse ordependence

• Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with anagent that is active against HIV-1 including but not limited to adefovir, tenofovir,entecavir, emtricitabine, or lamivudine

• Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovirbefore the first dose of study drug

• Has participated in a study with an investigational compound or device within 30 daysor anticipates participating in such a study during this study

• Has used systemic immunosuppressive therapy or immune modulators within 30 days or isanticipated to need them during the study (short courses of corticosteroids areallowed)

• Requires or is anticipated to require any of the following prohibited medicationswhile in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium,magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk ofMagnesia™

• Has significant hypersensitivity or other contraindication to any of the components ofthe study drugs

• Has current, active diagnosis of acute hepatitis due to any cause

• Is pregnant, breastfeeding, or expecting to conceive during the study

• Female participant expecting to donate eggs or male participant expecting to donatesperm during the study

• Is or has a family member (spouse or children) who is investigational staff or sponsorstaff directly involved in this trial